Study of AHB-171 in Chronic Hepatitis B Participants

Inclusion Criteria: * Able to fully understand and sign the informed consent form (ICF). * Male or female participants, aged 18-65 years (inclusive). * Body mass index (BMI) meeting the predefined eligibility range. * Chronic hepatitis B (CHB) participants with HBsAg or HBV DNA positivity for ≥6 months at screening. * At screening, participants meeting predefined ranges of HBsAg, HBV DNA, and ALT according to prior nucleos(t)ide analogue (NA) treatment history (stable prior treatment or treatment-naive), and meeting corresponding prior antiviral treatment duration requirements. * Adopt effective contraceptive measures as required Exclusion Criteria: * History of any severe systemic disease or malignancy other than chronic HBV infection which, in the opinion of the investigator, makes the subject unsuitable for study participation. * Prior history of solid organ or hematopoietic stem cell transplantation. * History of any other liver disease that the investigator considers unsuitable for trial.History of autoimmune disease or diseases with potential immune activation risk. * History or presence of hepatic decompensation at screening. * History of primary liver cancer, or diagnosis/suspected liver cancer at screening. * Imaging or histological evidence of significant liver fibrosis or cirrhosis within 12 months prior to screening, or a liver stiffness measurement indicative of significant fibrosis or cirrhosis at screening. Major trauma or major surgery within 12 weeks prior…